News for NKMAX CO., Ltd. (182400.KQ)

Published at

Dec 2, 2024 11:00 PM

by gurufocus.com

positive

positive

NKGen Biotech Selected as Stalking Horse Bidder for NKMax

Upon closing, the transaction would secure global IP rights for NKGen.NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other ma

182400.KQ

Read more →
Published at

Dec 2, 2024 10:28 PM

by manilatimes.net

positive

positive

NKGen Biotech Selected as Stalking Horse Bidder for NKMax

**media[481340]**

182400.KQ

Read more →
Published at

Nov 26, 2024 11:00 PM

by gurufocus.com

positive

positive

NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel

SANTA ANA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. ( NKGN) (”NKGen” or the ”Company”), today announced it received a notice (the

182400.KQ

Read more →
Published at

Nov 14, 2023 10:48 PM

by globenewswire.com

mixed

mixed

NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease,...

GFOR-UN GFOR 182400.KQ

Read more →
Published at

Oct 5, 2023 11:16 PM

by marketscreener.com

positive

positive

Graf Acquisition IV : Unaudited Condensed Consolidated Financial Statements - Form 8-K -October 05, 2023 at 05:16 pm EDT

Unaudited Condensed Consolidated Financial Statements Condensed Balance Sheets as of June 30, 2023 ...

SPGI.MX SPGI MHL.DE GFOR-UN GFOR AFMD 182400.KQ 0KYY.L

Read more →
Published at

May 25, 2023 7:05 PM

by globenewswire.com

positive

positive

NKGen Announces Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

SANTA ANA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and...

182400.KQ

Read more →
Published at

Apr 15, 2023 2:19 AM

by globenewswire.com

mixed

mixed

NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV

NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp....

GFOR-UN GFOR 182400.KQ

Read more →
Published at

Apr 13, 2021 3:30 PM

by marketscreener.com

positive

positive

NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC

SEOUL, South Korea, April 13, 2021 -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer cell therapies, announced the...

MKGAF 182400.KQ

Read more →